key: cord-0820868-vlbcppte
authors: Frankel, William C.; Yun, James J.; Weiss, Aaron J.
title: Commentary: Extracorporeal Membrane Oxygenation for COVID-19: A Step Towards Enlightenment? Or Still Flying Blind?
date: 2021-05-27
journal: J Thorac Cardiovasc Surg
DOI: 10.1016/j.jtcvs.2021.05.030
sha: 215bad3ad0bb73ce63d61333739b066f64fd112b
doc_id: 820868
cord_uid: vlbcppte

nan

The environment in which we found ourselves during the first wave of the Coronavirus disease 2019 (COVID-19) pandemic demanded rapid resource mobilization and a constantly adapting approach. In critically ill patients with acute respiratory failure refractory to lung protective ventilator strategies, limited therapeutic options exist. At centers with the requisite resources, extracorporeal membrane oxygenation (ECMO) can be considered if appropriate and feasible. ECMO in patients with acute respiratory failure from other etiologies has been investigated previously, 1-3 however, there are limited data regarding its use in COVID-19 patients.

In this context, the retrospective multi-center study by Saeed The cumulative in-hospital mortality at 90 days was 42%, which is in accordance with the rate of 37% reported in the international Extracorporeal Life Support Organization registry. 5 There were also comparable rates of major morbidity including secondary infection, stroke, and need for renal replacement therapy. In the multivariable analysis, age, serum creatinine, and prior cardiopulmonary resuscitation were identified as independent predictors of mortality. Although not surprising that young patients with preserved renal function placed on ECMO prior to cardiopulmonary collapse had the best chance of survival, the study also revealed those who died were 1) nearly a decade older and 2) placed on ECMO ~4 days later than those who survived.

We believe the latter in particular reflects the critical importance of an experienced multidisciplinary team that can expeditiously evaluate, prognosticate, and initiate ECMO in appropriately selected patients.

Although mainly a reflection of the significant challenge generating collaborative multicenter data during the early stages of the pandemic, the reader must be tempered in their derived conclusions due to inherent sampling bias in terms of which study sites were included, heterogeneity in management between centers (example, circuit scheme, cannulation site, anticoagulation regimen), and suboptimal granular data capture (example, relevant comorbidities, ventilator strategies, use of adjunctive renal replacement therapy, quality of life follow-up). Of the ~50% of patients who were discharged/transferred alive, >80% were sent home or to a rehabilitation facility. These outcomes are encouraging, however, more detailed

Efficacy and economic assessment of conventional ventilatory support versus extracorporeal membrane oxygenation for severe adult respiratory failure (CESAR): A multicentre randomised controlled trial

Extracorporeal membrane oxygenation for severe acute respiratory distress syndrome

Venovenous extracorporeal membrane oxygenation for acute respiratory distress syndrome: a systematic review and meta-analysis

Characteristics and Outcomes of Patients with COVID-19 Supported by Extracorporeal Membrane Oxygenation: A Retrospective Multicenter Study

Extracorporeal membrane oxygenation support in COVID-19: An international cohort study of the Extracorporeal Life Support Organization registry

Extracorporeal membrane oxygenation for patients with COVID-19 in severe respiratory failure